{
    "id": "ca1a42e2-f129-462a-8e87-a034da71862b",
    "indications": {
        "text": "ezetimibe simvastatin ezetimibe simvastatin combination simvastatin ezetimibe indicated : \u2022 adjunct diet reduce elevated low density lipoprotein cholesterol ( ldl-c ) : adults primary hyperlipidemia . adults pediatric patients aged 10 years older heterozygous familial hypercholesterolemia ( hefh ) . \u2022 adjunct ldl-c-lowering therapies reduce elevated ldl-c adults homozygous familial hypercholesterolemia ( hofh ) . simvastatin simvastatin , used component ezetimibe simvastatin , indicated reduce risk total mortality reducing risk coronary heart disease death , non-fatal myocardial infarction stroke , need coronary non-coronary revascularization procedures adults established coronary heart disease , cerebrovascular disease , peripheral vascular disease , and/or diabetes , high risk coronary heart disease events .",
        "doid_entities": [
            {
                "text": "familial hypercholesterolemia (DOID:13810)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_13810"
            },
            {
                "text": "coronary heart disease (DOID:3393)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_3393"
            },
            {
                "text": "heart disease (DOID:114)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_114"
            },
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            },
            {
                "text": "myocardial infarction (DOID:5844)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_5844"
            },
            {
                "text": "stroke (DOID:6713)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_6713"
            },
            {
                "text": "peripheral vascular disease (DOID:341)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_341"
            },
            {
                "text": "vascular disease (DOID:178)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_178"
            },
            {
                "text": "diabetes (DOID:9351)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_9351"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "important information : ( 2.1 ) take ezetimibe simvastatin orally daily evening without food . maximum recommended ezetimibe simvastatin 10/40 mg daily . ezetimibe simvastatin 10/80 mg daily restricted patients taking ezetimibe simvastatin 10/80 mg daily chronically ( e.g . , 12 months ) without evidence muscle toxicity . patients require high-intensity statin unable achieve ldl-c goal receiving ezetimibe simvastatin 10/40 mg daily , prescribe alternative ldl-c-lowering treatment . dose missed , take missed dose soon possible . double next dose . assess ldl-c clinically appropriate , early 2 weeks initiating ezetimibe simvastatin , adjust necessary . adults : recommended range 10/10 mg 10/40 mg daily . ( 2.2 ) full prescribing information ezetimibe simvastatin modifications due . ( 2.3 ) patients renal impairment : doses exceeding 10/20 mg used caution close monitoring patients moderate severe renal impairment . ( 2.4 )",
        "doid_entities": [],
        "orphanet_entities": [
            {
                "disease": "severe renal impairment",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_447788"
            }
        ]
    },
    "warningsAndPrecautions": "ezetimibe simvastatin tablets 10/10 , ( ezetimibe , usp 10 mg/simvastatin , usp 10 mg tablets ) white off-white , capsule shaped tablets debossed \u201c a029 \u201d one side plain side . supplied follows : ndc 67877-507-30 bottles 30 ndc 67877-507-90 bottles 90 ndc 67877-507-01 bottles 1000 ( repackaged blisters , opaque light-resistant blisters used . ) ndc 67877-507-38 carton 100 ( 10 x 10 ) unit-dose tablets ezetimibe simvastatin tablets 10/20 , ( ezetimibe , usp 10 mg/simvastatin , usp 20 mg tablets ) white off-white , capsule shaped tablets debossed \u201c a028 \u201d one side plain side . supplied follows : ndc 67877-508-30 bottles 30 ndc 67877-508-90 bottles 90 ndc 67877-508-01 bottles 1000 ( repackaged blisters , opaque light-resistant blisters used . ) ndc 67877-508-38 carton 100 ( 10 x 10 ) unit-dose tablets ezetimibe simvastatin tablets 10/40 , ( ezetimibe , usp 10 mg/simvastatin , usp 40 mg tablets ) white off-white , capsule shaped tablets debossed \u201c a027 \u201d one side plain side . supplied follows : ndc 67877-509-30 bottles 30 ndc 67877-509-90 bottles 90 ndc 67877-509-05 bottles 500 ( repackaged blisters , opaque light-resistant blisters used . ) ndc 67877-509-37 carton 50 ( 5 x 10 ) unit-dose tablets ezetimibe simvastatin tablets 10/80 , ( ezetimibe , usp 10 mg/simvastatin , usp 80 mg tablets ) white off-white , capsule shaped tablets debossed \u201c a026 \u201d one side plain side . supplied follows : ndc 67877-510-30 bottles 30 ndc 67877-510-90 bottles 90 ndc 67877-510-05 bottles 500 ( repackaged blisters , opaque light-resistant blisters used . ) ndc 67877-510-37 carton 50 ( 5 x 10 ) unit-dose tablets storage store 20 25o c ( 68 77 ) . [ usp controlled room temperature . ] keep container tightly closed .",
    "adverseReactions": "ezetimibe simvastatin tablets contraindicated following conditions : concomitant strong cyp3a4 inhibitors ( select azole anti-fungals , macrolide antibiotics , anti\u00adviral medications , nefazodone ) [ ( 7.1 ) ] . concomitant cyclosporine , danazol , danazol [ ( 7.1 ) ] . acute liver failure decompensated cirrhosis [ ( 5.3 ) ] . hypersensitivity simvastatin , ezetimibe , excipients ezetimibe simvastatin tablets . hypersensitivity , including anaphylaxis , angioedema , stevens-johnson syndrome , reported [ ( 6.2 ) ] .",
    "ingredients": [
        {
            "name": "EZETIMIBE",
            "code": "EOR26LQQ24",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_49040"
        },
        {
            "name": "SIMVASTATIN",
            "code": "AGG2FN16EV",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_9150"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14158"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_16189"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "ISOPROPYL ALCOHOL",
            "code": "ND2M416302",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30879"
        },
        {
            "name": "PROPYL GALLATE",
            "code": "8D4SNN7V92",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_16918"
        },
        {
            "name": "BUTYLATED HYDROXYANISOLE",
            "code": "REK4960K2U",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_76359"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "CITRIC ACID MONOHYDRATE",
            "code": "2968PHW8QP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_31404"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_15377"
        }
    ],
    "organization": "Ascend Laboratories, LLC",
    "name": "Ezetimibe and Simvastatin",
    "effectiveTime": "20250502",
    "indications_original": "Ezetimibe and Simvastatin\n                  \n                  Ezetimibe and simvastatin is a combination of simvastatin and ezetimibe indicated:\n                  \u2022 As an adjunct to diet to reduce elevated low density lipoprotein cholesterol (LDL-C):\n                  o In adults with primary hyperlipidemia.\n                  o In adults and pediatric patients aged 10 years and older with\n                  \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 heterozygous familial hypercholesterolemia (HeFH).\n                  \u2022 As an adjunct to other LDL-C-lowering therapies to reduce elevated LDL-C in adults with homozygous familial hypercholesterolemia (HoFH).\n                  \n                     Simvastatin\n                  \n                  Simvastatin, when used as a component of ezetimibe and simvastatin, is indicated to reduce the risk of total mortality by reducing risk of coronary heart disease death, non-fatal myocardial infarction and stroke, and the need for coronary and non-coronary revascularization procedures in adults with established coronary heart disease, cerebrovascular disease, peripheral vascular disease, and/or diabetes, who are at high risk of coronary heart disease events.",
    "contraindications_original": "Important Dosage and Administration Information: (2.1) Take ezetimibe and simvastatin orally once daily in the evening with or without food. Maximum recommended dosage is ezetimibe and simvastatin 10/40 mg once daily. Ezetimibe and simvastatin 10/80 mg daily dosage is restricted to patients who have been taking ezetimibe and simvastatin 10/80 mg daily chronically (e.g., for 12 months or more) without evidence of muscle toxicity. For patients that require a high-intensity statin or are unable to achieve their LDL-C goal receiving ezetimibe and simvastatin 10/40 mg daily, prescribe alternative LDL-C-lowering treatment. If as dose is missed, take the missed dose as soon as possible. Do not double the next dose. Assess LDL-C when clinically appropriate, as early as 2 weeks after initiating ezetimibe and simvastatin, and adjust the dosage if necessary. Adults: Recommended dosage range of 10/10 mg to 10/40 mg once daily. (2.2) See full prescribing information for ezetimibe and simvastatin dosage modifications due to drug interactions. (2.3) Patients with Renal Impairment: Doses exceeding 10/20 mg should be used with caution and close monitoring in patients with moderate to severe renal impairment. (2.4)",
    "warningsAndPrecautions_original": "Ezetimibe and simvastatin tablets 10/10, (ezetimibe, USP 10 mg/simvastatin, USP 10 mg tablets) are white to off-white, capsule shaped tablets debossed with \u201cA029\u201d on one side and plain on other side.\n                             They are supplied as follows:     NDC 67877-507-30 bottles of 30     NDC 67877-507-90 bottles of 90     NDC 67877-507-01 bottles of 1000 (If repackaged in blisters, then opaque or light-resistant blisters should be used.)     NDC\u00a0 67877-507-38\u00a0 carton of 100 (10 x 10) unit-dose tablets\n                  \n                  \n                     Ezetimibe and simvastatin tablets 10/20, (ezetimibe, USP 10 mg/simvastatin, USP 20 mg tablets) are white to off-white, capsule shaped tablets debossed with \u201cA028\u201d on one side and plain on other side.     \u00a0     They are supplied as follows:     NDC 67877-508-30 bottles of 30     NDC 67877-508-90 bottles of 90     NDC 67877-508-01 bottles of 1000 (If repackaged in blisters, then opaque or light-resistant blisters should be used.)     NDC 67877-508-38 carton of 100 (10 x 10) unit-dose tablets\n                  \n                  \n                     Ezetimibe and simvastatin tablets 10/40, (ezetimibe, USP 10 mg/simvastatin, USP 40 mg tablets) are white to off-white, capsule shaped tablets debossed with \u201cA027\u201d on one side and plain on other side.\n                             They are supplied as follows:     NDC 67877-509-30 bottles of 30     NDC 67877-509-90 bottles of 90     NDC 67877-509-05 bottles of 500 (If repackaged in blisters, then opaque or light-resistant blisters should be used.)     NDC 67877-509-37 carton of 50 (5 x 10) unit-dose tablets\n                  \n                  \n                     Ezetimibe and simvastatin tablets 10/80, (ezetimibe, USP 10 mg/simvastatin, USP 80 mg tablets) are white to off-white, capsule shaped tablets debossed with \u201cA026\u201d on one side and plain on other side.\n                             They are supplied as follows:     NDC 67877-510-30 bottles of 30     NDC 67877-510-90 bottles of 90     NDC 67877-510-05 bottles of 500 (If repackaged in blisters, then opaque or light-resistant blisters should be used.)     NDC 67877-510-37 carton of 50 (5 x 10) unit-dose tablets\n                  \n                  Storage \n                  Store at 20 to 25o C (68 to 77 oF). [See USP Controlled Room Temperature.] Keep container tightly closed.",
    "adverseReactions_original": "Ezetimibe and simvastatin tablets is contraindicated in the following conditions: \n                  \n                     Concomitant use of strong CYP3A4 inhibitors (select azole anti-fungals, macrolide antibiotics, anti\u00adviral medications, and nefazodone) [see Drug Interactions (7.1)]. \n                     Concomitant use of cyclosporine, danazol, or danazol [see Drug Interactions (7.1)]. \n                     Acute liver failure or decompensated cirrhosis [see Warnings and Precautions (5.3)].\n                     Hypersensitivity to simvastatin, ezetimibe, or any excipients in ezetimibe and simvastatin tablets. Hypersensitivity reactions, including anaphylaxis, angioedema, and Stevens-Johnson syndrome, have been reported [see Adverse Reactions (6.2)].",
    "drug": [
        {
            "name": "Ezetimibe and Simvastatin",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_49040"
        }
    ]
}